Tutorial on statistical considerations on subgroup analysis in confirmatory clinical trials

被引:52
作者
Alosh, Mohamed [1 ]
Huque, Mohammad F. [2 ]
Bretz, Frank [3 ,4 ]
D'Agostino, Ralph B., Sr. [5 ]
机构
[1] US FDA, Div Biometr 3, Off Biostat, OTS,CDER, Silver Spring, MD 20993 USA
[2] US FDA, Off Biostat, OTS, CDER, Silver Spring, MD 20993 USA
[3] Novartis, Stat Methodol & Consulting, Basel, Switzerland
[4] Med Univ Vienna, Ctr Med Stat Informat & Intelligent Syst, Vienna, Austria
[5] Boston Univ, Dept Math & Stat, Boston, MA 02215 USA
关键词
negative subgroup treatment effect; treatment-by-subgroup interaction; supportive subgroup findings; targeted subgroup; MULTIPLE END-POINTS; SEVERE SEPSIS; DESIGN; ENRICHMENT; ALPHA; CONSISTENCY; FRAMEWORK; EFFICACY; CANCER;
D O I
10.1002/sim.7167
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Clinical trials target patients who are expected to benefit from a new treatment under investigation. However, the magnitude of the treatment benefit, if it exists, often depends on the patient baseline characteristics. It is therefore important to investigate the consistency of the treatment effect across subgroups to ensure a proper interpretation of positive study findings in the overall population. Such assessments can provide guidance on how the treatment should be used. However, great care has to be taken when interpreting consistency results. An observed heterogeneity in treatment effect across subgroups can arise because of chance alone, whereas true heterogeneity may be difficult to detect by standard statistical tests because of their low power. This tutorial considers issues related to subgroup analyses and their impact on the interpretation of findings of completed trials that met their main objectives. In addition, we provide guidance on the design and analysis of clinical trials that account for the expected heterogeneity of treatment effects across subgroups by establishing treatment benefit in a pre-defined targeted subgroup and/or the overall population. Copyright (C) 2016 John Wiley & Sons, Ltd.
引用
收藏
页码:1334 / 1360
页数:27
相关论文
共 50 条
[1]   Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death [J].
Abraham, E ;
Laterre, P ;
Garg, R ;
Levy, H ;
Talwar, D ;
Trzaskoma, BL ;
Francois, B ;
Guy, JS ;
Bruckmann, M ;
Rea-Neto, A ;
Rossaint, R ;
Perrotin, D ;
Sablotzki, A ;
Arkins, N ;
Utterback, BG ;
Macias, WL .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (13) :1332-1341
[2]   Statistical Considerations on Subgroup Analysis in Clinical Trials [J].
Alosh, Mohamed ;
Fritsch, Kathleen ;
Huque, Mohammad ;
Mahjoob, Kooros ;
Pennello, Gene ;
Rothmann, Mark ;
Russek-Cohen, Estelle ;
Smith, Fraser ;
Wilson, Stephen ;
Yue, Lilly .
STATISTICS IN BIOPHARMACEUTICAL RESEARCH, 2015, 7 (04) :286-304
[3]   STATISTICAL PERSPECTIVES ON SUBGROUP ANALYSIS: TESTING FOR HETEROGENEITY AND EVALUATING ERROR RATE FOR THE COMPLEMENTARY SUBGROUP [J].
Alosh, Mohamed ;
Huque, Mohammad F. ;
Koch, Gary G. .
JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2015, 25 (06) :1161-1178
[4]   Multiplicity considerations for subgroup analysis subject to consistency constraint [J].
Alosh, Mohamed ;
Huque, Mohammad F. .
BIOMETRICAL JOURNAL, 2013, 55 (03) :444-462
[5]   A flexible strategy for testing subgroups and overall population [J].
Alosh, Mohamed ;
Huque, Mohammad F. .
STATISTICS IN MEDICINE, 2009, 28 (01) :3-23
[6]   Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer [J].
Amado, Rafael G. ;
Wolf, Michael ;
Peeters, Marc ;
Van Cutsem, Eric ;
Siena, Salvatore ;
Freeman, Daniel J. ;
Juan, Todd ;
Sikorski, Robert ;
Suggs, Sid ;
Radinsky, Robert ;
Patterson, Scott D. ;
Chang, David D. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (10) :1626-1634
[7]   No inconsistent trial assessments by NICE and IQWiG: different assessment goals may lead to different assessment results regarding subgroup analyses [J].
Bender, Ralf ;
Koch, Armin ;
Skipka, Guido ;
Kaiser, Thomas ;
Lange, Stefan .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 2010, 63 (12) :1305-1307
[8]   Efficacy and safety of recombinant human activated protein C for severe sepsis. [J].
Bernard, GR ;
Vincent, JL ;
Laterre, P ;
LaRosa, SP ;
Dhainaut, JF ;
Lopez-Rodriguez, A ;
Steingrub, JS ;
Garber, GE ;
Helterbrand, JD ;
Ely, EW ;
Fisher, CJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (10) :699-709
[9]   Multiplicity and replicability: two sides of the same coin [J].
Bretz, Frank ;
Westfall, Peter H. .
PHARMACEUTICAL STATISTICS, 2014, 13 (06) :343-344
[10]   A graphical approach to sequentially rejective multiple test procedures [J].
Bretz, Frank ;
Maurer, W. ;
Brannath, Werner ;
Posch, Martin .
STATISTICS IN MEDICINE, 2009, 28 (04) :586-604